Collaborative Agreements (Details 4) (USD $)	3 Months Ended		9 Months Ended		24 Months Ended			1 Months Ended					1 Months Ended			9 Months Ended	24 Months Ended								9 Months Ended					9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Oct. 31, 2012 Novartis	Oct. 31, 2012 Novartis Future Technological Improvements	Oct. 31, 2012 Novartis Research Services	Nov. 30, 2013 Novartis Right-to-test agreement	Oct. 31, 2013 Novartis Right-to-test agreement item	Mar. 31, 2013 Novartis Right-to-test agreement	Oct. 31, 2010 Novartis Right-to-test agreement	Mar. 31, 2014 Novartis Right-to-test agreement	Mar. 31, 2013 Novartis Right-to-test agreement Undisclosed Target item	Mar. 31, 2013 Novartis Right-to-test agreement Minimum Undisclosed Target	Mar. 31, 2013 Novartis Right-to-test agreement Exclusive license Undisclosed Target item	Mar. 31, 2014 Novartis Development and Commercialization License	Oct. 31, 2012 Novartis Development and Commercialization License	Oct. 31, 2010 Novartis Development and Commercialization License	Nov. 30, 2013 Novartis Development and Commercialization License Maximum	Oct. 31, 2013 Novartis Development and Commercialization License Maximum	Mar. 31, 2013 Novartis Development and Commercialization License Maximum	Oct. 31, 2010 Novartis Development and Commercialization License Maximum	Mar. 31, 2013 Novartis Development and Commercialization License Development milestones	Oct. 31, 2010 Novartis Development and Commercialization License Development milestones	Mar. 31, 2014 Novartis Development and Commercialization License Development milestones Phase I clinical trial item	Mar. 31, 2013 Novartis Development and Commercialization License Regulatory milestones	Oct. 31, 2010 Novartis Development and Commercialization License Regulatory milestones	Mar. 31, 2013 Novartis Development and Commercialization License Sales milestones	Oct. 31, 2010 Novartis Development and Commercialization License Sales milestones	Mar. 31, 2014 Novartis Development and Commercialization License Exclusive license item
Collaborative Agreements disclosures
Term of agreement											3 years
Term of extension of the agreement									1 year
Payments for extension of agreement									$ 5,000,000
Number of extension terms									1
Additional term of extension of the agreement									1 year
Payments received under collaboration agreement					60,200,000	4,500,000	710,000	1,000,000	1,000,000	1,000,000	45,000,000						55,000,000
License exercise fee, per license																		1,000,000
Potential milestone payments																			199,500,000	199,500,000	199,500,000	199,500,000	22,500,000	22,500,000	5,000,000	77,000,000	77,000,000	100,000,000	100,000,000
Number of development and commercialization licenses taken																									3					2
Number of pre-defined and related undisclosed targets													2		1															2
License exercise fee, for the fourth license												1,000,000
Agreed upon fee receivable on conversion of non-exclusive target to an exclusive target														5,000,000
Payments received under collaboration agreement in connection with amended agreement										3,500,000
Potential milestone payments under second option																					238,000,000		22,500,000			115,500,000		100,000,000
Amount of arrangement consideration included in license and milestone fees	305,000	22,010,000	39,150,000	23,372,000												17,200,000
Cumulative catch-up amount included in license and milestone fees																$ 1,000,000
Estimated utilization period after commercialization																10 years
Discount rate (as a percent)																16.00%
Estimated term of development and commercialization license																25 years